Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Abstract Background As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens needs to be assessed. Hepatitis C virus (HCV) genotype 3 is associated w...

Full description

Bibliographic Details
Main Authors: Phil McEwan, Samantha Webster, Thomas Ward, Michael Brenner, Anupama Kalsekar, Yong Yuan
Format: Article
Language:English
Published: BMC 2017-07-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Hepatitis C virus
Daclatasvir
Cost-effectiveness
Sofosbuvir
Online Access:http://link.springer.com/article/10.1186/s12962-017-0077-4

Internet

http://link.springer.com/article/10.1186/s12962-017-0077-4

Similar Items